1st International and 10th National Iranian Conference on Bioinformatics
Home Accepted Papers
Spike/ membrane multi-epitope based protein as a future candidate vaccine against sars-cov-2
Paper ID : 1240-ICB10
Authors:
آرمیتی کیومرثی1, محمد رضا شفاعتی *2, مسعود قربانی3, شقایق یزدانی4, وحید ضرغامی5, فرزانه کاظمیان فر6
1میکروبیولوژی، علوم و فناوری های نوین، دانشگاه آزاد اسلامی واحد علوم پزشکی تهران، تهران، ایران
2گروه زیست شناسی سلولی و مولکولی، دانشکده علوم پایه، واحد همدان، دانشگاه آزاد اسلامی، همدان، ایران
3موسسه پاستور ایران، مجتمع تحقیق و تولید، گروه تحقیقات و توسعه، کرج، ایران.
4گروه میکروبیولوژی، دانشکده علوم و فناوری نوین. علوم پزشکی تهران، دانشگاه آزاد اسلامی، تهران، ایران
5موسسه علوم نانو و فناوری نانو، دانشگاه صنعتی شریف، تهران، ایران.
6دپارتمان عفونی، گروه داخلی، بیمارستان شهید فیاض بخش، دانشگاه علوم پزشکی ایران، تهران، ایران
Abstract:
Since humans are not immune to SARS-COV-2, it is urgent to produce vaccines to reduce epidemics and prevent the reappearance of SARS-CoV-2 and possible variants of this virus. This study aimed to design a multivalent recombinant protein based on SARS-CoV-2 virus spike and Membrane epitopes associated with HSP70 of Mycobacterium tuberculosis bacteria to evaluate the induced immune response to enhance the immune response induced by the recombinant SARS-CoV-2 vaccine. Initially, to select the appropriate strain for extraction of membrane and viral spike, phylogenetic analysis was performed . Then, based on the frequency of HLA in the population of Iran and the Middle East , three HLA-A*02:01 and HLA-C*04:01 and HLA-DRB1*01:01 were selected to predict T cell epitopes . These epitopes were divided into two groups of GP100 and GP200 and were connected to HLA-A and HLA-C, and from each group, protein candidates were selected. Then, two selected proteins, and whole protein HSP70 tuberculosis were attached by suitable linkers and analyzed immunogenicity, antigenicity, the allergenicity of these recombinant proteins , and one protein was selected as a final protein candidate. In our laboratory, this triple cassette was cloned into a clone donor and transected into the expression host of Bacillus subtilis. Results: The increase in antibody titer against SARS-COV-2 in mice immunized with the recombinant vaccine was significant. Discussion and Conclusion: This achievement shows that an increase in humoral and cellular immune response from the recombinant vaccine of SARS-COV-2 based on the epitopes can be used as an effective candidate vaccine against the possible epidemics caused by this Virus and possible variants of this virus.
Keywords:
SARS-CoV-2; Immunogenicity; Antigenicity; Allergenicity; Recombinant protein design; Candidate Vaccine;
Status : Paper Accepted (Poster Presentation)